Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 33525; 33525 cream; Lulicon; Lulicon Cream 1%; Lulicon Solution 1%; Lulifin; Luzu; NND-502

Latest Information Update: 02 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nihon Nohyaku
  • Developer Ortho Dermatologics; POLA PHARMA; Sun Pharmaceutical Industries; Tinea Pharmaceuticals Inc
  • Class Antifungals; Imidazoles; Skin disorder therapies; Small molecules
  • Mechanism of Action Sterol demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mycoses; Tinea corporis; Tinea cruris; Tinea pedis
  • Phase II/III Onychomycosis

Most Recent Events

  • 27 Jul 2017 Valeant Pharmaceuticals International acquired Ortho Dermatologics in 2011 and changed the name of the later to Valeant Dermatology. Subsequently, in July 2017, it was rebranded to Ortho Dermatologics
  • 08 Feb 2016 Launched for Tinea corporis (In children, In adolescents) in Honduras, Dominican Republic (Topical) before February 2016
  • 16 Sep 2015 Antimicrobial data from a in vitro potency study in Onychomycosis released by TOPICA Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top